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Background: Adult height and insulin levels have independently been associated with breast 
cancer risk. However, little is known about whether these factors influence estradiol levels. 
Thus, we hypothesize that adult height in combination with insulin levels may influence 
premenopausal 17β-estradiol throughout the entire menstrual cycle of possible importance of 
breast cancer risk. 
Methods: Among 204 healthy women, aged 25-35 years who participated in the Norwegian 
EBBA I study, birth weight and age at menarche were assessed by questionnaire, personal 
health record and interview. 17β-estradiol concentrations were estimated by daily saliva 
samples throughout one entire menstrual cycle using radioimmunoassay (RIA). Measures of 
height (cm) were taken as well as waist circumference (cm), body mass index (BMI kg/m
2) 
and total fat percentage (DEXA % fat). Fasting blood samples were drawn, and serum 
concentrations of insulin were determined.  
Results: The women reported a mean height of 166.5 cm, birth weight of 3389 g and age at 
menarche 13.1 years. Mean BMI was 24.4 kg/m
2, mean waist circumference 79.5 cm and 
mean total fat percentage 34.1%. Women with an adult height of more than 170 cm and 
insulin levels higher than 90 pmol/L experienced on average an 37.2 % increase in 17β-
estradiol during an entire menstrual cycle compared to those with the same height, and insulin 
levels below 90 pmol/L. Moreover, this was also observed throughout the entire menstrual 
cycle. 
Conclusion: Our findings support that premenopausal levels of 17β-estradiol vary in response 
to adult height and insulin levels, suggesting that women who become taller are put at risk for 
higher estradiol levels when their insulin levels rise of possible importance for breast cancer 
risk. 
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Introduction 
Attained adult height has consistently been positively associated with the risk of 
 breast cancer  
[Palmer et al., 1995]. Genetic and early environmental factors are linked to attained height 
and therefore height may be a good marker not only on birth weight but also on susceptible 
periods of rapid growth and age at menarche. Additionally insulin and insulin resistance have 
been linked to birth size and sexual maturation as well as breast cell proliferation, suggested 
to influence breast cancer risk
  {2007 161 /id, Eliassen, 2007 2 /id}. 
  Obesity has been linked to mortality from the majority of cancers. The insulin/insulin-
like growth factor (IGF) system may partly explain this effect. The metabolic syndrome, 
associated with hyperinsulinemia, may modulate this effect. Recent evidence supports the role 
of insulin and IGF-1 as important growth factors, acting through the tyrosine kinase growth 
factor cascade in enhancing tumor cell proliferation. The role of insulin is of concern because 
of the increasing levels of obesity and the associated metabolic syndrome {Boyd, 2003 9 /id}, 
and may be of importance in relation to the carcinogenesis of the breast. 
To our knowledge, little is known about the association between adult height, insulin 
levels and premenopausal estradiol level throughout an entire menstrual cycle. However, the 
etiologic role of endogenous hormones as 17 β-estradiol in relation to breast cancer risk is 
strongly supported [Pike et al., 1993], [Bernstein, 2002]. Additionally, the large variation in 
breast cancer incidence and in levels of sex hormones has been discussed to reflect both 
genetic variation [Bernstein, 2002], {King, 1996 1 /id} as well as variation in availability of 
energetic factors [Jasienska and Thune, 2001]. Therefore, we hypothesize that a combination 
of adult height and insulin levels may interact, and influence levels of 17 β- estradiol 
throughout the entire menstrual cycle.  
Because steroid levels in saliva
 represent free, rather than free plus bound circulating 
steroid
 levels, they allow for much finer discrimination of functional
 differences in steroid 
signalling. Because saliva can be readily
 collected from subjects on multiple occasions, it is 
possible
 to compare steroid levels across entire menstrual cycles among
 different women 
rather than relying on one or a few timed blood
 samples{Lipson, 1996 112 /id, Jasienska, 
2006 4 /id}.  
The aim of the present study was to assess if levels of 17β-estradiol throughout an 
entire menstrual cycle are influenced by variation in adult height together with variation in 
insulin levels. Such interactive effect may be of possible importance for susceptibility of 
breast cancer. 
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Material and Methods 
Subjects and study design 
Women aged 25-35 years, living in Tromsø and surroundings during 2000-2002, were invited 
to participate in the Norwegian EBBA study by announcements in newspapers and locally. 
Study subjects had to meet the following criteria; self reported regular menstruation (normal 
cycle length; 22-38 days within the previous three months), not taking hormonal 
contraceptives, no pregnancy or lactation over the previous six months, no history of 
endocrinological, gynecological disorder or chronic disorders (e.g. diabetes, hypo-
/hyperthyroidism).  A total of 206 women who met the inclusion criteria, were subsequently 
enrolled into the study and came to the Department of Clinical Research, University Hospital 
North Norway (UNN), at a scheduled time [Furberg et al., 2004]. Two women were excluded: 
one because of a measured cycle length of 47 days and the other because of abnormally high 
E
2 levels. 
 
Questionnaires 
We used a general questionnaire (self-administered and by interview) to collect information 
on ethnicity, education, birth size, menstruation and reproductive history,  previous use of 
hormones, family history of cancer and lifestyle habits (lifetime total physical activity, 
smoking, alcohol). Recall and memory- probing aid and interview by trained personal were 
used, including a lifetime calendar. A pre-coded food diary with photographic booklet on 
portion size was developed and used in order to collect dietary data on seven different days 
(follicular phase; day 3-6 and luteal phase; day 21-23) during the menstrual cycle.  
 
Body composition measurements  
We measured attained height to the nearest half-centimeter with the women in standing 
position and with no footwear. 
Body mass index (BMI, kg/m
2) was used to estimate relative weight. Waist 
circumference (cm) was measured in a horizontal line 2.5 cm above the umbilicus. 
Age at menarche was assessed by questionnaire and interview by the same trained nurse.  
Study subjects made three subsequent visits to the laboratory over the course of one 
menstrual period: visit 1 (days 1-4), visit 2 (midcycle) and visit 3 (days 22-25). They came in 
on the first possible day after onset of the menstrual bleeding for clinical examinations, 
anthropometric measurements and for a fasting blood sample. All clinical procedures were                   04.06.2010   4 
conducted by trained nurses at the Department of Clinical Research, UNN, Tromsø. 
Anthropometrical measures were taken twice (visit 1, visit 3) with subjects wearing light 
clothing and no footwear: waist circumference were measured to the nearest half- centimeter 
and weight was measured to the nearest 0.1 kilogram on an electronic scale who were 
standardized on a regular basis.  
On the second visit (mid-cycle day 7-12) the participants met for whole body scan. 
Whole body scan was obtained by DEXA (DPX-L 2288, Lunar Radiation Corporation, 
Madison, WI, USA) operated by the trained nurse and percentage of fat tissue was estimated 
by Lunar software.  
 
Serum samples  
Fasting serum blood samples were drawn from an ante-cubital vein three times during the 
menstrual cycle (visit I, visit II and visit III). The blood was centrifuged and the serum was 
separated. Serum concentrations of estradiol were measured in fresh sera at the Department of 
Clinical Chemistry, UNN, Tromsø.  Serum concentrations of insulin and leptin were 
measured at the Hormone Laboratory, Aker University Hospital, Oslo in serum that were 
stored at -70˚C for up to 3 years until analysis. Serum insulin and leptin were measured by 
RIA using kits from Linco Research Inc, St. Charles, MO, USA [Furberg et al., 2004]. 
 
Estradiol indices and assay procedure 
From the first day of bleeding  and each day during the menstrual cycle the participants 
collected morning saliva samples at home according to previously established collection 
protocols at the Reproductive Ecology Laboratory at Harvard University, U.S.A, [Lipson and 
Ellison, 1996].Concentrations of 17 β-estradiol were measured in daily saliva samples from 
20 days (reverse cycle day –5 to –24)  of the cycle using an 
125 I
- based radioimmunoassay 
(RIA) kit (#39100, Diagnostic Systems Laboratory, Webster, TX, USA), along with published 
modifications of the manufacturer’s protocol [Furberg et al., 2005]. All samples were run in 
duplicate. All of a woman’s samples were run in the same batch, with women randomly 
assigned to batches. CV’s were calculated from high to low value pools (appropriate to the 
range of 17 β-estradiol) that were run with each batch [Furberg et al., 2005]. 
Before statistical analysis, all cycles were aligned to the day of ovulation following 
published methods [Furberg et al., 2005], based on the identification of the E2 drop at the 
mid-cycle (day 0), which provides a reasonable estimate of the day of ovulation. The E2 
values for 20 consecutive days from each cycle, aligned on day 0, were used in data analyses                   04.06.2010   5 
(day -10 to + 9). Satisfactory identification of the mid-cycle E2 drop could not be made for 14 
women and their cycles were not aligned. 
 
Statistical analysis 
We studied the association between adult height, insulin and 17 β- estradiol levels throughout 
a menstrual cycle using linear regression analysis and linear mixed models for repeated 
measures (SAS statistical package version 9.1).  
In order in detail to study the influence of variation in attained adult height on 
estradiol levels, the study population was divided into tertiles of adult height; 1) < 164cm, 2) 
≥164cm and <170cm and 3) ≥170cm. These three groups of adult height were then compared 
with regard to selected characteristics of the study population. We used one-way analyses of 
variance for continuous variables and χ
2 tests for categorical variables.  
Age and multivariate adjusted linear regression analyses were used to study the 
associations of average salivary 17β-estradiol concentration (overall, follicular and luteal 
phases of menstrual cycle), adult height and measures of body composition, serum insulin, 
leptin and cholesterol.  
To study whether variation in insulin levels modified the association between adult 
height and salivary concentrations of 17β-estradiol, insulin levels were dichotomized at the 
75th percentile (75th percentile insulin: ≥ 90). We used a linear mixed model for repeated 
measures to study salivary 17β-estradiol concentrations over the entire menstrual cycle in 
relation to adult height and levels of insulin.  
In order to adjust for potential confounding factors multivariate analyses were 
performed. Based on biological plausibility possible covariates such as age, smoking, physical 
activity, age at menarche, energy intake, alcohol, previous use of hormonal contraceptives, 
age at first birth and number of children were tested in the model. The following variables 
fitted the model and were therefore included in the final model; age, smoking, physical 
activity and age at menarche. We have presented both age adjusted and multivariate adjusted 
estimates. 
Measurements of 17β-estradiol at the start and finish of the cycles had higher 
coefficients of variation and higher rates of missing data as a result of variation in cycle 
length; therefore we included 17β-estradiol measurements from cycle day −10 to +9 in the 
linear mixed models. Results were considered statistically significant when the two-sided p 
value was < 0.05.                   04.06.2010   6 
 
 
Ethical Consideration 
All the participating women signed an informed consent form. The study protocol was 
reviewed and approved by the Regional Committee for Medical Research Ethics and the 
Norwegian Data Inspectorate.  
 
Results 
When dividing the women into tertiles of adult height (<164 cm, 164-170 cm, >170 cm), they 
did not vary much by their characteristics. However, women within the highest tertile of adult 
height (≥170cm) had a larger waist circumference (p= 0.008) compared to those with a 
shorter adult height, but they did not seem to have a greater BMI or total fat % than those who 
become smaller. Of interest, the tallest women tend to have higher insulin levels, and they had 
later age at menarche (p=0.02).  
We studied the changes in overall average salivary 17β-estradiol concentration by 1 
standard deviation (SD) change in explanatory variables for each tertile of adult height; birth 
weight (DS= x), BMI (SD= 3.8  ), waist (SD=  9.8 ) and by 1 SD change in serum leptin (SD= 
562.9 ) or insulin (SD= 59.2 ) and cholesterol (SD= 0.78). We observed that an increase in 
any of these measures except for birth weight resulted in a multi-adjusted increase in 17β-
estradiol concentration in the highest tertile of adult height (≥170cm), (Table 2). For each SD 
change in insulin levels in the highest tertile of adult height, the overall multi-adjusted level of 
17 beta-estradiol increased by 3.1 pmol/L (95 % CI, 1.1, 5.2), quivalent to a 17.3 % change in 
mean average concentration of 17 β-estradiol in the highest tertile of adult height. For each 
SD change in BMI in the highest tertile of adult height, the overall multi-adjusted level of 17 
beta-estradiol increased by 3.0 pmol/L (95 % CI, 0.8, 5.3), equivalent to a 16.8 % change in 
mean average concentration of 17 β-estradiol in the highest tertile of adult height. 
For each SD increase in explanatory variables, except for insulin, 17 β-estradiol seem 
to increase also among women in the lowest tertile of adult height (<164), - although not to 
the same degree as among the tallest women. 
  In order to study the association between adult height, insulin levels and 17 β-estradiol 
we used a linear mixed model for repeated measures to study salivary estradiol concentrations 
throughout an entire menstrual cycle in relation to adult height and insulin levels (proc 
mixed), (Figure 1, 2). We observed no clear pattern between daily 17 β-estradiol and variation 
in attained adult height or between daily 17 β-estradiol and variation in levels of insulin                   04.06.2010   7 
(figures not shown). In contrast, when analyzing the association between adult height in 
combination with insulin levels and 17 β-estradiol, we observed that height in combination 
with insulin were associated with levels of premenopausal 17 β- estradiol throughout the 
menstrual cycle. Women in the highest tertile of attained height (>170cm) in combination 
with the highest tertile of insulin (≥90) experienced on average 37.2 % increase in 17β-
estradiol during an entire menstrual cycle compared to those with the same height, and insulin 
levels below 90 pmol/L, (Figure 1). The results became even more pronounced when we 
looked into those with adult attained height in the upper quartile ≥172 cm and insulin≥90 
(p=0.006), (Figure 2). 
 
Discussion 
In our study among young healthy and regular menstrual cycling women, we found that tall 
women with an adult height ≥170cm in combination with increased insulin levels (insulin 
levels ≥90), experienced 37.2 % increase in free 17 β-estradiol levels during each menstrual 
cycle compared to women with an adult height ≥ 170 cm and serum insulin < 90 pmol/L.  
To our knowledge no other studies have looked into the interrelationship of attained adult 
height, serum insulin levels and 17β-estradiol levels over an entire menstrual cycle. 
  Height is a result of both genetics and nutrition. Nutrition during periods of growth 
(childhood and puberty) seems to be an especially important factor for final height [Cold et 
al., 1998] [Tretli and Gaard, 1996]. Thus, height may be a proxy-variable of nutritional status 
during the years of growth. Consequently, attained height has been proposed as an indicator 
of childhood energy intake and it has been suggested that early exposures that possibly affect 
mammary mass [Albanes and Winick, 1988] may also be critical in breast carcinogenesis 
[Hunter and Willett, 1993].  
  Changes in life style that occurred during World War II in Norway affected children’s 
height as well as their weight (Brundtland et al 1980). The most obvious reason for the 
reduction in growth-rate during this period was a change in nutrition [Vatten and Kvinnsland, 
1990]. The incidence of breast cancer was lower than expected among women who 
experienced puberty during the war. The estimated configuration of the exposure variable 
showed an increase in exposure up to the start of WWII to twice the level in 1916, dropped by 
13 percent during the war, and increased again after the war.[Tretli and Gaard, 1996]. This 
may support height as an important factor in relation to breast cancer risk. 
  Li et al found that age when maximum height was attained was related to breast 
cancer risk rather than attained height [Li et al., 1997]. The physiologic basis for this                   04.06.2010   8 
observation may be that if women reach their maximum height later, their breasts mature later 
and, consequently, they have less time between their pubertal breast development and the 
protective breast proliferation that occurs at the time of the first live birth [Li et al., 1997]. 
However, height may also reflect the number of ductal stem cells that develop in the breast in 
utero, which implicates prenatal exposures in breast cancer aetiology [Trichopoulos and 
Lipman, 1992]. Attained height is also probably influenced by inherited patterns in 
endogenous hormones and growth factors that influence risk at puberty when breast tissue is 
rapidly developing in addition to promoting effects later in life. Dietary exposures other than 
energy deprivation may influence height, including an overabundance of energy and fat and 
variation in macronutrient intake in the years before puberty [Ziegler et al., 1996]. It has been 
suggested that better nutrition accelerates growth hormone release, which then increases 
insulin-like growth factor (IGF) levels[Stoll and Secreto, 1992]. The adolescent growth spurt 
involves stimulation by growth hormone, insulin, IGF and sex steroids, and one hypothesis is 
that the combination of IGF and sex steroids results in mitogenic effects on developing 
mammary tissue in adolescence and, therefore, an increased risk of epithelial atypia and 
carcinogenesis [Stoll, 1998]  
Furthermore, abdominal-type obesity and higher circulating levels of insulin, testosterone and 
insulin-like growth factor 1 are further risk markers for breast cancer. {Stoll, 1994 1 
/id}.Recent theories propose that a Western lifestyle may increase cancer risk through 
alterations in the metabolism of insulin and insulin-like growth factors (IGF),[Keown-Eyssen, 
1994]; [Giovannucci, 1995]; [Kaaks, 1996]; [Werner and LeRoith, 1996]. Insulin regulates 
energy metabolism, and increases the bioactivity of IGF-I by enhancing its synthesis, and by 
decreasing several of its binding proteins (IGFBP; IGFBP-1 and -2). Insulin and IGF-I both 
stimulate anabolic processes as a function of available energy and elementary substrates (e.g. 
amino acids). The anabolic signals by insulin or IGF-I can promote tumour development by 
inhibiting apoptosis, and by stimulating cell proliferation. Furthermore, both insulin and IGF-I 
stimulate the synthesis of sex steroids, and inhibit the synthesis of sex hormone-binding 
globulin (SHBG), a binding protein that regulates the bioavailability of circulating sex 
steroids to tissues [Kaaks and Lukanova, 2001]. Epidemiological evidence is accumulating 
and suggests that the risk of cancers of the colon, pancreas, endometrium, breast and prostate 
are related to circulating levels of insulin, IGF-1, or both [Kaaks, 2004].  
  Weight gain, through typical Western diet; limited levels of activity; and, more 
recently, stress-related changes in neuroendocrine function may lead to insulin resistance and 
hyperinsulinemia. The opportunity for a multidisciplinary approach involving nutrition,                   04.06.2010   9 
exercise, and stress reduction in an integrative setting may be crucial to limiting the insulin-
resistant state and improving cancer outcomes{Boyd, 2003 9 /id}. 
  Despite the inverse relation on an ecologic (population) trend
 level, the analyses show 
that earlier age at menarche in individuals
 is related to shorter adult height. The latter may 
appear contradictory
 to the known effects of age at menarche and height on breast
 cancer risk. 
It is likely, however, that these risk factors
 affect breast cancer risk through different 
pathways. Early
 menarche may lead to an increased lifetime exposure to endogenous
 sex 
hormones, which may cause an increased risk of breast cancer
 (36 –38 ). Taller adult height, 
on the other hand, is positively
 associated with high levels of growth hormone and insulin-like
 
growth factor I and might be a reflection of increased growth
 hormone/insulin-like growth 
factor I activity during childhood,
 which is also hypothesized to increase breast cancer 
risk[Kaaks and Lukanova, 2001] 
To our knowledge little is known about the relationship between adult height, adult 
body composition, serum insulin levels and 17β-estradiol throughout an entire menstrual 
cycle. However, epidemiological evidence implicating anthropometric risk factors in breast 
cancer aetiology is accumulating. Most previous studies have found a positive association 
between breast cancer and height [Cold et al., 1998]. The evidence is somewhat stronger from 
the cohort than the case–control studies, possibly because most cohort studies use direct 
measures of height while the majority of case–control studies use self-reported height. Among 
studies that could examine the risks by menopausal status, weaker associations are found for 
premenopausal women [Friedenreich, 2001]. Overall, the range of risks estimated from 
studies for taller, as compared to shorter, women is 0.8–2.0 for premenopausal women and 
1.3–1.9 for postmenopausal women [Ballard-Barbash, 1994]. Women with a family history of 
breast cancer experience a greater risk with increased height (RR~2.0) than do women 
without such a family history (RR~1.2) [Ballard-Barbash, 1994]. 
The daily saliva sampling allowed for estimation of daily 17 β-estradiol concentrations 
throughout one entire menstrual cycle which strengthen our study. We used well-developed 
and validated methods and assays to characterize the women’s exposure to free, biologically 
active ovarian steroids and the comparisons of levels by aligned cycle days {Lipson, 1996 136 
/id}. This study has the benefit of having collected samples every day over an entire 
menstrual cycle, as opposed to a random or selected day within a cycle. Furthermore, salivary 
levels of 17β-estradiol are quite stable within participants over time [Ellison and Lipson, 
1999].                   04.06.2010   10 
The use of one clinical research department at a university hospital with one specially 
trained nurse enhanced the quality of our data. It also allowed us to sample all clinical 
variables within the same narrow frame of the cycle for each participant, using uniform 
procedures. To limit any potential influence of season, women did not participate during 
months with no daylight (December and January). Height was measured according to 
standardized methods.  Insulin was estimated in fasting serum samples after being stored not 
more than 3 years and then analyzed at The Aker University Hospital using well documented 
methods. We adjusted for potential confounders. 
 
Conclusion: Our main findings suggest that taller women are put at risk for higher 17β-
estradiol levels when their insulin levels rise. This may influence levels of 17β-estradiol 
during each menstrual cycle of possible importance for breast cancer risk. 
Our findings support the hypothesis that tallness in combination with adult obesity and 
thereby elevated levels of insulin may influence biomarkers of importance for breast cancer 
risk.  
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Table 1 Characteristics of the study population by height (cm), means, (SD)* (tertiles). The 
Norwegian EBBA-Study (N=204**) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Characteristics 
 
 
<164 
n=68 
Height 
≥164-- 170 
n=68 
≥170 
n=68 
 
 
p-value ‡ 
(trend) 
Age, Years  31.1 (1.3)  30.3 (3.3)  30.7 (3.0)   
Years of schooling         
Ethnic minority, sami %         
Anthropometric measurements         
  BMI, kg/m
2  23.9 (3.2)  25.2 (4.0)  24.1 (4.0)  0.9 
  Waist circumference, cm  76.5 (7.9)  80.9 (10.2)  81.1 (10.5)  0.008 
  Total fat, %  33.2 (7.7)  35.2 (7.7)  34.0 (7.4)  0.55 
Saliva hormone concentrations, pmol/l         
  Overall 17 beta-estradiol  16.8 (8.1)  19.7 (8.5)  17.2 (9.6)  0.83 
Serum hormone concentration ≡ (mmol/l)          
  s-Estradiol    0.14 (0.05)  0.15 (0.1)  0.15 (0.1)   
                s-leptin  716.5 (4.2.2)  941.9 (606.9)  901.2 (625.7)   
                s-glucose  5.0 (0.6)  5.0 (0.5)  5.1 (0.6)   
                s-insulin  79.6 (65.1)  85.4 (43.0)  91.8 (67.0)  0.23 
 Menstrual and reproductive 
characteristics 
 
   
 
  Menarche  12.9 (1.3)  13.0 (1.3)  13.4 (1.5)  0.02 
  Age at 1. birth, years ║  24.5 (4.4)  24.1 (4.1)  24.9 (3.2)   
  Number of children  0.9 (1.0)  0.9 (1.2)  1.0 (1.2)   
  Cycle length, days  28.0 (2.8)  28.3 (3.0)  28.4 (3.7)                     04.06.2010   12 
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